Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis
Tarun Kaushik, Muhammad Magdi YaqoobBarts Health NHS Trust, William Harvey Research Unit, London, UKAbstract: Peginesatide is the newest erythropoietin-stimulating agent (ESA) in the quest for the ideal treatment of anemia in chronic kidney disease (CKD) patients. Reduced frequency of administration...
Guardado en:
Autores principales: | Kaushik T, Yaqoob MM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/44fb5b1bb52f4c109ffa20b0fc6d9b12 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide
por: Valliant A, et al.
Publicado: (2013) -
A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis.
por: Himanshu Naik, et al.
Publicado: (2013) -
HYPERURICEMIA IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS. A SINGLE CENTRE EXPERIENCE
por: Mohsin Qayyum, et al.
Publicado: (2019) -
Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility
por: Davis-Ajami ML, et al.
Publicado: (2014) -
Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
por: Ishii T, et al.
Publicado: (2021)